Back to Results

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

Greeley Campus
Harmony Campus
Highlands Ranch Hospital
Medical Center of the Rockies
Poudre Valley Hospital
University of Colorado Hospital

Principal Investigator
Jose Pacheco

Jose Pacheco

Study ID

Protocol Number: 19-1121

ClinicalTrials.gov: NCT03793179

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers